The United States Antibody‑Drug Conjugate (ADC) for Solid Tumors market size was valued at approximately USD 0.55 billion in 2025. The market is projected to grow from approximately USD 0.58 billion in 2026 to around USD 1.04 billion by 2034, exhibiting a CAGR of about 8.9% during the forecast period. Antibody‑Drug Conjugates are targeted therapeutics that combine a monoclonal antibody that...